Anti-BRAF/MEK therapies (i.e., dabrafenib/trametinib or encorafenib/binimetinib) improve survival for Class I BRAF-mutant NSCLC and are recommended for frontline use by clinical guidelines (12–14). Here, MAP2K7 is linked to non-small cell lung carcinoma.